Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Synergistic Colistin–Gamithromycin Therapy in Neutropenic Pn

    2026-08-01

    Synergistic Colistin–Gamithromycin Therapy in Neutropenic Pneumonia

    Study Background and Research Question

    Pasteurella multocida is a significant Gram-negative pathogen implicated in respiratory diseases such as bovine respiratory disease (BRD), which inflicts considerable economic losses on livestock industries globally—over $3 billion annually according to the reference study. Due to the diversity of P. multocida serotypes and the corresponding challenge in effective vaccine coverage, antibiotic therapy remains essential. However, the emergence of multidrug resistance, particularly to macrolides and colistin, necessitates the development of new therapeutic strategies. The study by Li et al. specifically investigates whether combining colistin, a last-resort polymyxin antibiotic, with gamithromycin, a modern macrolide, can enhance antimicrobial activity against P. multocida in a neutropenic murine model—a clinically relevant scenario given the immunocompromised state of many infected hosts.

    Key Innovation from the Reference Study

    The central innovation of this work is the demonstration that colistin and gamithromycin exhibit potent synergistic effects when administered together, leading to marked reductions in the minimal inhibitory concentrations (MICs) required for each agent. This synergy was particularly evident in isolates of P. multocida with high baseline colistin resistance. Importantly, the combination therapy allowed for up to 256-fold reductions in colistin dosing and up to 8-fold reductions in gamithromycin dosing compared to monotherapies—a finding with clear implications for dose optimization and resistance management (reference study).

    Methods and Experimental Design Insights

    The investigators employed a rigorous multi-step approach to evaluate synergy. Initially, nine distinct clinical P. multocida isolates with varying colistin sensitivities were screened for in vitro susceptibility to both drugs, alone and in combination. Three representative isolates—two with high colistin MICs (D18 and T5) and one with a low MIC (WJ11)—were selected for detailed time-kill analyses and in vivo efficacy studies in a neutropenic murine lung infection model. Neutropenia was induced pharmacologically, mimicking compromised host immunity, thus increasing model translatability to real-world clinical scenarios. Pharmacokinetic (PK) and pharmacodynamic (PD) assessments were integrated, with plasma drug concentrations measured and the AUC(0–24 h)/MIC index calculated to correlate drug exposure with microbiological outcome. The study also determined gamithromycin dosing requirements for effective combined therapy, finding that these were reduced 6- to 35-fold relative to monotherapy.

    Protocol Parameters

    • Neutropenia induction: Cyclophosphamide administered to mice prior to infection to induce neutropenia and model immunocompromised states.
    • Antibiotic dosing: Colistin and gamithromycin administered individually and in combination; dosages titrated based on MIC profiles of each P. multocida isolate.
    • Time-kill assays: Performed over 24 hours with sampled time points to assess rapidity and extent of bacterial clearance.
    • PK/PD modeling: AUC(0–24 h)/MIC index used to quantify pharmacodynamic efficacy; high correlation (>0.89) observed between drug exposure and bacterial kill rate.
    • Murine lung infection model: Intranasal inoculation of P. multocida in neutropenic mice, followed by therapy and quantitative lung bacterial burden assessment.

    Core Findings and Why They Matter

    The combination of colistin and gamithromycin achieved robust bactericidal effects against P. multocida in both in vitro time-kill studies and the neutropenic murine lung model. Notably, synergy was most pronounced in strains with high colistin resistance, translating to up to 256-fold reductions in required colistin concentrations and 8-fold reductions for gamithromycin. These findings indicate that combined therapy can not only extend the utility of existing antibiotics but also help circumvent resistance mechanisms—critical in the context of increasing multidrug-resistant Gram-negative pathogens.

    Moreover, the study found that, regardless of baseline MIC differences, the combination therapy achieved comparable drug concentrations and bactericidal effects across diverse isolates. This suggests the potential for standardized dosing regimens and improved predictability of therapeutic outcomes. The tight correlation between the AUC(0–24 h)/MIC index and antimicrobial efficacy further supports rational PK/PD-guided dosing strategies in future translational research and clinical application (reference study).

    Comparison with Existing Internal Articles

    Several internal resources reinforce and contextualize the findings of this reference study. For instance, the article "Synergistic Colistin-Gamithromycin Therapy in Neutropenic Lung Infection" similarly highlights enhanced antimicrobial efficacy and the potential for combination regimens to overcome resistance in difficult-to-treat Gram-negative infections. Another resource, "Synergistic Colistin and Gamithromycin Therapy in Murine Pneumonia", expands on the clinical relevance of the observed synergy, specifically emphasizing dosage reductions and the mechanistic insights provided by combination therapy. These articles collectively underscore the translational value of the reference study, particularly for researchers developing new therapeutic protocols for respiratory infections caused by multidrug-resistant organisms.

    Limitations and Transferability

    While the study’s neutropenic murine lung infection model offers high relevance for immunocompromised host scenarios, several limitations should be noted. First, the findings pertain specifically to P. multocida and may not directly extrapolate to other Gram-negative pathogens without further validation. Second, although the combination dramatically reduced required drug concentrations, potential toxicity—particularly nephrotoxicity associated with colistin—remains a concern and demands cautious clinical translation. Third, resistance mechanisms specific to gamithromycin, including erm(E) and msr(E)–mph(E), may still pose challenges in the field, necessitating ongoing surveillance. Finally, while the PK/PD modeling provides a robust framework for dose optimization, additional studies are required to confirm these results in broader animal models and in clinical settings.

    Research Support Resources

    For researchers aiming to model immunosuppression in infection studies or study apoptosis induction in cancer cells, Cyclophosphamide (SKU A2343) is a well-characterized alkylating chemotherapeutic agent that can be used to induce neutropenia in murine models, similar to protocols described in the reference study. Its established utility in both cancer research and immune modulation workflows makes it a practical choice for experimental setups requiring controlled immunosuppression. Detailed solubility, storage, and protocol guidance is available via the APExBIO product page. Researchers should adhere to protocol-specific dosing and safety recommendations to ensure reproducibility and model fidelity.